• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Discover Financial Services Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket

    2/20/24 8:09:16 AM ET
    $AGMH
    $AGRI
    $COF
    $DDC
    EDP Services
    Technology
    Metal Fabrications
    Industrials
    Get the next $AGMH alert in real time by email

    Shares of Discover Financial Services (NYSE:DFS) shares rose sharply in today’s pre-market trading.

    Capital One Financial Corp (NYSE:COF) announced its plans to purchase Discover Financial Services, marking a pivotal $35.3 billion all-stock transaction.

    As per the terms of the deal, Discover shareholders are slated to receive 1.0192 shares of Capital One for every share they hold, translating to a 26% premium over Discover's last closing price.

    Discover Financial Services shares jumped 11.2% to $122.88 in pre-market trading

    Here are some other stocks moving in pre-market trading.

    Gainers

    • AgriFORCE Growing Systems Ltd. (NASDAQ:AGRI) gained 283.1% to $0.82 in pre-market trading. AgriFORCE was granted patent from the USPTO related to its FORCEGH+ facilities
    • Shineco, Inc. (NASDAQ:SISI) shares jumped 156% to $3.77 in pre-market trading after surging more than 16% on Friday. Shineco recently announced plans for a 1-for-10 reverse stock split to regain compliance with Nasdaq minimum bid requirement.
    • TRxADE HEALTH, Inc. (NASDAQ:MEDS) shares rose 100.4% to $8.30 in pre-market trading. TRxADE HEALTH announced the sale of assets of subsidiary Trxade, Inc. to Micro Merchant Systems for $22.5 million, with potential additional $7.5 million payout.
    • Enviva Inc. (NYSE:EVA) shares surged 51.5% to $0.4953 in pre-market trading after falling around 12% on Friday. The Wall Street Journal recently reported that Enviva was preparing to file for bankruptcy.
    • Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) shares rose 41.2% to $12.92 in pre-market trading. Iovance's AMTAGVI received the U.S. FDA accelerated approval for advanced melanoma.
    • D-Wave Quantum Inc. (NYSE:QBST) shares gained 40.2% to $2.44 in pre-market trading. NEC and D-Wave introduced new quantum offerings to the Australian market.
    • Ocugen, Inc. (NASDAQ:OCGN) gained 39.1% to $1.32 in pre-market trading after jumping 27% on Friday.
    • DDC Enterprise Limited (NYSE:DDC) gained 31.3% to $2.73 in pre-market trading after surging around 7% on Friday.
    • Ostin Technology Group Co., Ltd. (NASDAQ:OST) shares rose 25.8% to $0.8669 in pre-market trading after gaining over 16% on Friday.

    Losers

    • Universe Pharmaceuticals INC (NASDAQ:UPC) shares dipped 30.9% to $1.70 in pre-market trading after gaining around 44% on Friday.
    • MicroCloud Hologram Inc. (NASDAQ:HOLO) shares fell 26% to $49.14 in pre-market trading after jumping 114% on Friday.
    • Gaxos.ai Inc. (NASDAQ:GXAI) shares declined 22.8% to $0.5450 in pre-market trading after surging 173% on Friday. The company announced that its gaming division will launch an AI solution for game developers and studios.
    • Tarena International, Inc. (NASDAQ:TCTM) fell 22.8% to $1.39 in pre-market trading after gaining 64% on Friday.
    • FLJ Group Limited (NASDAQ:FLJ) shares tumbled 22.8% to $0.9111 in pre-market trading. FLJ Group filed annual report on Form 20-F for fiscal year 2023.
    • Oriental Culture Holding LTD (NASDAQ:OCG) shares fell 20.9% to $1.40 in pre-market trading after gaining 21% on Friday.
    • Tevogen Bio Holdings Inc. (NASDAQ:TVGN) shares fell 18.8% to $7.72 in pre-market trading. Tevogen Bio recently announced an $8 million equity investment.
    • Lichen China Limited (NASDAQ:LICN) dipped 18% to $1.14 in pre-market trading after gaining around 19% on Friday.
    • Tian Ruixiang Holdings Ltd (NASDAQ:TIRX) shares fell 17.8% to $0.6988 in pre-market trading after gaining 42% on Friday.
    • AGM Group Holdings Inc. (NASDAQ:AGMH) shares declined 17.6% to $1.53 in pre-market trading.

     

    Now Read This: Walmart, Home Depot And 3 Stocks To Watch Heading Into Tuesday

    Get the next $AGMH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGMH
    $AGRI
    $COF
    $DDC

    CompanyDatePrice TargetRatingAnalyst
    Tevogen Bio Holdings Inc.
    $TVGN
    3/4/2026Buy → Hold
    D. Boral Capital
    Iovance Biotherapeutics Inc.
    $IOVA
    2/25/2026$5.00Mkt Perform → Mkt Outperform
    Citizens
    Capital One Financial Corporation
    $COF
    12/8/2025$270.00Outperform
    Wolfe Research
    Capital One Financial Corporation
    $COF
    8/1/2025$290.00Buy
    Rothschild & Co Redburn
    Iovance Biotherapeutics Inc.
    $IOVA
    7/15/2025$1.00Neutral → Sell
    Goldman
    Capital One Financial Corporation
    $COF
    7/8/2025$258.00Hold → Buy
    TD Cowen
    Iovance Biotherapeutics Inc.
    $IOVA
    5/16/2025$2.00Buy → Neutral
    UBS
    Iovance Biotherapeutics Inc.
    $IOVA
    5/12/2025Buy → Hold
    Truist
    More analyst ratings

    $AGMH
    $AGRI
    $COF
    $DDC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tevogen Bio downgraded by D. Boral Capital

    D. Boral Capital downgraded Tevogen Bio from Buy to Hold

    3/4/26 9:36:27 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Iovance Biotherapeutics upgraded by Citizens with a new price target

    Citizens upgraded Iovance Biotherapeutics from Mkt Perform to Mkt Outperform and set a new price target of $5.00

    2/25/26 7:38:09 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wolfe Research resumed coverage on Capital One with a new price target

    Wolfe Research resumed coverage of Capital One with a rating of Outperform and set a new price target of $270.00

    12/8/25 8:33:41 AM ET
    $COF
    Major Banks
    Finance

    $AGMH
    $AGRI
    $COF
    $DDC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Major General Malcolm B. Frost (Ret.) of the US Army Joins America First Defense Drone and Robotics Advisory Council

    U.S. Army Commanding General (Ret.) to Help Guide Next-Generation Counter-Drone Innovation, AI and Robotics Roseland, NJ, March 10, 2026 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various high-growth sectors, today announced that Malcolm B. Frost, a retired Major General in the United States Army, has joined America First Defense ("AFD") Drone and Robotics Advisory Council. Major General Frost brings decades of operational and strategic experience in modern warfare, military communications, and advanced defense technologies. Throughout his distinguished career, he held multiple senior leadership roles wi

    3/10/26 8:12:00 AM ET
    $GXAI
    Computer Software: Prepackaged Software
    Technology

    Tevogen Names Leadership Team to Execute Diversified Growth Strategy

    WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced the appointment of interim leaders across its core business verticals to execute the first phase of its diversified growth strategy. In this first phase, Tevogen is evaluating strategic opportunities that, if completed, are expected to operate as subsidiaries of the Company and could collectively generate annual revenues exceeding $50 million. The Company expects these transactions to close by the second quarter of 2026, subject to customary due diligence and definitive agreements. Leadership Designations: Digital Health: Arpita Patel and Wojtek StobinskiGene

    3/9/26 7:45:00 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Letter to Shareholders from CEO Dr. Ryan Saadi

    WARREN, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN). Dear Shareholders, As we continue executing on Tevogen's long-term strategy to evolve into a sustainable, revenue-generating healthcare enterprise, I would like to provide an update regarding our ongoing strategic initiatives. Over the past several months, we have been actively evaluating potential acquisitions designed to complement our existing immunotherapy and artificial intelligence platforms. If consummated, these transactions are expected to operate as subsidiaries of Tevogen resulting in positive cash flow generation and a return on invested capital over time. Base

    3/6/26 3:40:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGMH
    $AGRI
    $COF
    $DDC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Welch David Ryan was granted 97,410 shares and bought $1,424 worth of shares (11 units at $129.42), increasing direct ownership by 647% to 97,421 units (SEC Form 4)

    4 - AGRIFORCE GROWING SYSTEMS LTD. (0001826397) (Issuer)

    9/30/25 7:56:59 PM ET
    $AGRI
    Metal Fabrications
    Industrials

    Chief Commercial Officer Kirby Daniel Gordon bought $55,200 worth of shares (30,000 units at $1.84) (SEC Form 4)

    4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

    6/6/25 4:05:31 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Regulatory Officer Puri Raj K. bought $9,743 worth of shares (5,600 units at $1.74), increasing direct ownership by 3% to 206,852 units (SEC Form 4)

    4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

    5/27/25 4:06:43 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGMH
    $AGRI
    $COF
    $DDC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Interim CEO & General Counsel Vogt Frederick G converted options into 62,493 shares and covered exercise/tax liability with 26,755 shares, increasing direct ownership by 7% to 529,538 units (SEC Form 4)

    4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

    3/6/26 5:02:10 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Graf Finckenstein Friedrich converted options into 31,246 shares and covered exercise/tax liability with 16,520 shares, increasing direct ownership by 13% to 131,957 units (SEC Form 4)

    4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

    3/6/26 5:01:35 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Regulatory Officer Puri Raj K. converted options into 39,059 shares and covered exercise/tax liability with 18,360 shares, increasing direct ownership by 9% to 239,230 units (SEC Form 4)

    4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

    3/6/26 5:00:45 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGMH
    $AGRI
    $COF
    $DDC
    SEC Filings

    View All

    SEC Form S-8 filed by Ocugen Inc.

    S-8 - Ocugen, Inc. (0001372299) (Filer)

    3/4/26 12:23:26 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Ocugen Inc.

    10-K - Ocugen, Inc. (0001372299) (Filer)

    3/4/26 11:38:01 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Ocugen, Inc. (0001372299) (Filer)

    3/4/26 11:12:21 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGMH
    $AGRI
    $COF
    $DDC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

    For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

    2/16/24 3:48:47 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGMH
    $AGRI
    $COF
    $DDC
    Leadership Updates

    Live Leadership Updates

    View All

    Tevogen Names Leadership Team to Execute Diversified Growth Strategy

    WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced the appointment of interim leaders across its core business verticals to execute the first phase of its diversified growth strategy. In this first phase, Tevogen is evaluating strategic opportunities that, if completed, are expected to operate as subsidiaries of the Company and could collectively generate annual revenues exceeding $50 million. The Company expects these transactions to close by the second quarter of 2026, subject to customary due diligence and definitive agreements. Leadership Designations: Digital Health: Arpita Patel and Wojtek StobinskiGene

    3/9/26 7:45:00 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

    MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). "Mrs. Johnson-Greene's diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen's CFO," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "We look forward to her leadership as we enter into a transformative time at Ocugen, beginning with the submission of the first of three Biologics License Applications (BLAs) this

    2/9/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oriental Culture Holding LTD Announces First Half Year of 2025 Unaudited Financial Results

    HONG KONG, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Oriental Culture Holding LTD. ("OCG" or the "Company") (NASDAQ:OCG), an online provider of collectibles and artwork e-commerce services, today announced its unaudited financial results for the six months ended June 30, 2025. First Half Year of 2025 Financial Highlights Total revenues were approximately $0.1 million for the six months ended June 30, 2025, compared with the total revenues of approximately $0.4 million for the six months ended June 30, 2024.Gross profit was approximately $0.1 million for the six months ended June 30, 2025, compared with approximately gross profit of $0.3 million for the six months ended June 30, 2024.Gross margin

    11/14/25 4:20:00 PM ET
    $OCG
    Other Consumer Services
    Consumer Discretionary

    $AGMH
    $AGRI
    $COF
    $DDC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tevogen Bio Holdings Inc.

    SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)

    11/14/24 5:29:01 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc.

    SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

    11/14/24 4:50:30 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Gaxos.ai Inc.

    SC 13G - GAXOS.AI INC. (0001895618) (Subject)

    11/14/24 3:30:50 PM ET
    $GXAI
    Computer Software: Prepackaged Software
    Technology

    $AGMH
    $AGRI
    $COF
    $DDC
    Financials

    Live finance-specific insights

    View All

    Gaxos Acquires Strategic Stake in America First Defense, Developer of Advanced Drone-Based Electronic Warfare System

    Acquisition Provides Exposure to Emerging US Defense Technologies with Multi-Sector National Security Applications Roseland, NJ, March 03, 2026 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various high-growth sectors, today announced that it acquired a 19.99% stake in America First Defense ("AFD"), a US-based defense technology company developing next-generation drone and robotics platforms. America First Defense is an American-owned defense technology company developing next-generation security platforms across both air and ground domains. The company is focused on two high-priority categories: a detachab

    3/3/26 8:12:00 AM ET
    $GXAI
    Computer Software: Prepackaged Software
    Technology

    Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results

    MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's fourth quarter and full year 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 4, 2026. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 3029428Webcast: Available on the events sec

    2/18/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DDC Surpasses 2,000 Bitcoin in Treasury Holdings with Additional 80 BTC Purchase

    DDC Enterprise Limited (NYSEAMERICAN: DDC) ("DDC" or the "Company"), a global Asian food platform and digital asset treasury company, today announced the acquisition of an additional 80 Bitcoin ("BTC"), bringing its corporate treasury to 2,068 BTC. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217100155/en/DDC Now Holds 2,068 BTC The latest purchase marks DDC's sixth consecutive week of Bitcoin accumulation and represents a 74.8% increase in holdings since the start of 2026, reinforcing BTC's role as a foundational component of the Company corporate treasury strategy. The transaction was executed under DDC's established ca

    2/17/26 8:00:00 AM ET
    $DDC
    Packaged Foods
    Consumer Staples